Despite many studies showing that the diabetes drug Actos is linked to an increased risk of developing bladder cancer, those in the industry are still trying to prove that is not true. The results of a recent large-scale study are now suggesting there is not a significant risk of bladder…
Actos is a medication used to treat patients with type II diabetes by keeping their blood glucose levels down. The medication is a member of a class of drugs, but only Actos seems to be linked to an increased risk for developing bladder cancer according to a recent news feature…
In Cooper v. Takeda Pharmaceuticals, an appeal from the Court of Appeal for the State of California, Second Appellate District, a husband and wife filed a lawsuit against Takeda Pharmaceuticals in which they alleged defendant’s Actos drug was responsible for husband’s bladder cancer, with which he was diagnosed in 2011.…
Despite ongoing litigation surrounding the diabetes drug Actos, the Japanese drug manufacturer, Takeda Pharmaceutical Co Ltd, seems to be pushing ahead with sales and conducting studies to find new markets for its medication. According to a recent article from Reuters, a German study shows Actos may delay the onset of…
In the wake of a $9 billion verdict against Japanese drugmaker Takeda Pharmaceuticals, the manufacturer of diabetes drug Actos, which has been causally connected to instances of bladder cancer, the number of lawsuits filed against the firm continues. Boston Actos injury attorneys recognize that in reality, that $9 billion will…
Takeda Pharmaceuticals is facing pending legal action in a multidistrict litigation because the company’s drug, Actos, significantly increases the risk of patients developing bladder cancer. Plaintiffs have been successful in past cases in taking legal action against the pharmaceutical company, with one jury awarding $9 million in damages. However, some…
A federal jury is preparing to hear a bellwether case regarding the alleged cancer-causing diabetes drug Actos, manufactured by Asia’s largest drugmaker, Takeda Pharmaceuticals. The plaintiff in Terrence Allen et ux. v. Takeda Pharmaceuticals North America Inc. et al alleges damages in excess of $75,000 after he says he developed…